Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graves Ophthalmopathy | 2 | 2022 | 13 | 0.860 |
Why?
|
| Exophthalmos | 2 | 2022 | 18 | 0.860 |
Why?
|
| Eyelid Diseases | 2 | 2022 | 26 | 0.830 |
Why?
|
| Drug Costs | 2 | 2016 | 117 | 0.820 |
Why?
|
| Eye Diseases | 3 | 2021 | 97 | 0.750 |
Why?
|
| Health Care Costs | 2 | 2016 | 425 | 0.700 |
Why?
|
| Ophthalmologists | 2 | 2020 | 20 | 0.640 |
Why?
|
| Methotrexate | 2 | 2016 | 233 | 0.550 |
Why?
|
| Hemifacial Spasm | 1 | 2018 | 2 | 0.540 |
Why?
|
| Blepharospasm | 1 | 2018 | 7 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 1365 | 0.540 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 47 | 0.510 |
Why?
|
| Rheumatologists | 1 | 2016 | 15 | 0.490 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 19 | 0.490 |
Why?
|
| Azathioprine | 1 | 2016 | 44 | 0.480 |
Why?
|
| Arthritis, Juvenile | 1 | 2016 | 60 | 0.460 |
Why?
|
| Insurance, Health | 2 | 2016 | 310 | 0.450 |
Why?
|
| Glucocorticoids | 2 | 2016 | 531 | 0.440 |
Why?
|
| Uveitis, Posterior | 1 | 2014 | 12 | 0.430 |
Why?
|
| Uveitis | 1 | 2016 | 149 | 0.430 |
Why?
|
| Uveitis, Intermediate | 1 | 2014 | 8 | 0.430 |
Why?
|
| Vision Disorders | 1 | 2016 | 179 | 0.430 |
Why?
|
| Eyelid Neoplasms | 2 | 2024 | 10 | 0.380 |
Why?
|
| Ophthalmology | 3 | 2020 | 119 | 0.240 |
Why?
|
| Corneal Diseases | 1 | 2025 | 46 | 0.220 |
Why?
|
| Specialization | 2 | 2016 | 135 | 0.210 |
Why?
|
| Mohs Surgery | 1 | 2024 | 29 | 0.200 |
Why?
|
| Cornea | 1 | 2025 | 154 | 0.200 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2022 | 2 | 0.190 |
Why?
|
| Eye Hemorrhage | 1 | 2022 | 3 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2024 | 142 | 0.180 |
Why?
|
| Visual Acuity | 1 | 2025 | 491 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2020 | 1188 | 0.180 |
Why?
|
| Blepharitis | 1 | 2022 | 9 | 0.180 |
Why?
|
| Keratitis | 1 | 2022 | 20 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 837 | 0.170 |
Why?
|
| Ophthalmoplegia | 1 | 2021 | 13 | 0.170 |
Why?
|
| Trochlear Nerve Diseases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Cavernous Sinus | 1 | 2021 | 16 | 0.170 |
Why?
|
| Mucormycosis | 1 | 2021 | 18 | 0.170 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2021 | 9 | 0.170 |
Why?
|
| Population Health | 1 | 2021 | 44 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 6055 | 0.160 |
Why?
|
| Orbital Diseases | 1 | 2021 | 37 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 143 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2022 | 992 | 0.140 |
Why?
|
| Decision Making | 2 | 2016 | 974 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 483 | 0.130 |
Why?
|
| Triage | 1 | 2020 | 250 | 0.130 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 307 | 0.130 |
Why?
|
| Injections | 1 | 2018 | 198 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2016 | 153 | 0.120 |
Why?
|
| Humans | 16 | 2025 | 145140 | 0.110 |
Why?
|
| Rheumatology | 1 | 2016 | 133 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 848 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2016 | 535 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2020 | 862 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 362 | 0.090 |
Why?
|
| Quality of Life | 1 | 2025 | 3194 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 517 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 733 | 0.090 |
Why?
|
| Female | 7 | 2025 | 78636 | 0.080 |
Why?
|
| Middle Aged | 4 | 2025 | 36126 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2016 | 696 | 0.080 |
Why?
|
| United States | 3 | 2021 | 16065 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17247 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 5886 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 2377 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2024 | 708 | 0.070 |
Why?
|
| Adult | 3 | 2025 | 40665 | 0.060 |
Why?
|
| Male | 5 | 2025 | 72664 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 8035 | 0.060 |
Why?
|
| Blepharoplasty | 1 | 2024 | 9 | 0.050 |
Why?
|
| Eyelids | 1 | 2024 | 41 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 26 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 8318 | 0.040 |
Why?
|
| Oculomotor Muscles | 1 | 2022 | 86 | 0.040 |
Why?
|
| Adolescent | 1 | 2021 | 22479 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 323 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 11 | 0.040 |
Why?
|
| Ketosis | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 168 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2021 | 305 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 177 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 26096 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 447 | 0.030 |
Why?
|
| Sinusitis | 1 | 2021 | 227 | 0.030 |
Why?
|
| Documentation | 1 | 2020 | 199 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2022 | 822 | 0.030 |
Why?
|
| Child | 1 | 2016 | 22670 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1320 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3410 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2020 | 1240 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2767 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 11741 | 0.020 |
Why?
|